Portfolio

 

Proprietary Pipeline

Preclinical phase
Clinical phase
 
Project, Mechanism
 
Disease area
 
Discovery
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Remetinostat
Topical HDAC inhibitor
Cutaneous T-cell lymphoma
Basal cell carcinoma (Stanford investigator sponsored study)
Birinapant
SMAC mimetic
Solid tumors
(combo with Keytruda™)
High-grade serous carcinomas
MIV-818
Nucleotide DNA polymerase inhibitor
Hepatocellular carcinoma
Leukotide
Nucleotide DNA polymerase inhibitor
Acute Myeloid Leukemia (AML) and other hematological cancers
MIV-711
Cathepsin K inhibitor
Osteoarthritis
MIV-323
Fusion protein inhibitor
RSV-infection

 

Partnership Pipeline

Preclinical phase
Clinical phase
 
Project
 
Disease area
 
Partner
 
Discovery
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Olysio
(Simeprevir)
Hepatitis C Janssen
Xerclear Labial herpes GSK and Meda
MIV-802
Nucleotide NS5B polymerase inhibitor
Hepatitis C Ascletis (Greater China) Trek Therapeutics (rest of world)

 

Page updated 10 November 2017